Sarepta (SRPT) told Bloomberg that a patient died from acute liver failure after receiving its gene therapy in an early stage study. A company spokesperson said the patient died of acute liver failure last month in an early-stage trial to treat limb-girdle muscular dystrophy. The company previously disclosed that two patients taking Elevidys for Duchenne muscular dystrophy had died. Sarepta told regulators about the death “in an appropriate and timely manner,” the spokesperson added. Shares of Sarepta are down 36%, or $7.75, to $14.22 in premarket trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Positive Outlook for Sarepta Therapeutics Amid Strategic Reorganization and Risk Mitigation
- Sarepta price target lowered to $32 from $36 at Piper Sandler
- Sarepta price target lowered to $23 from $25 at RBC Capital
- Sarepta price target raised to $35 from $30 at Baird
- H.C. Wainwright keeps Sell on Sarepta with narrowing Elevidys market